JP7859982B2 - がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法 - Google Patents

がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Info

Publication number
JP7859982B2
JP7859982B2 JP2022554171A JP2022554171A JP7859982B2 JP 7859982 B2 JP7859982 B2 JP 7859982B2 JP 2022554171 A JP2022554171 A JP 2022554171A JP 2022554171 A JP2022554171 A JP 2022554171A JP 7859982 B2 JP7859982 B2 JP 7859982B2
Authority
JP
Japan
Prior art keywords
prodrug
ido
lipid
liposome
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502182A5 (cg-RX-API-DMAC7.html
JP2023502182A (ja
Inventor
デイビッド ストーバー,
ドゥルバ バラリ,
ブルース エー. ヘイ,
タハミネー サファイエ,
Original Assignee
ナミ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナミ セラピューティクス, インコーポレイテッド filed Critical ナミ セラピューティクス, インコーポレイテッド
Publication of JP2023502182A publication Critical patent/JP2023502182A/ja
Publication of JP2023502182A5 publication Critical patent/JP2023502182A5/ja
Priority to JP2025052649A priority Critical patent/JP2025092573A/ja
Application granted granted Critical
Publication of JP7859982B2 publication Critical patent/JP7859982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022554171A 2019-11-12 2020-11-12 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法 Active JP7859982B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025052649A JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962974086P 2019-11-12 2019-11-12
US62/974,086 2019-11-12
PCT/US2020/000044 WO2021096542A1 (en) 2019-11-12 2020-11-12 Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025052649A Division JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Publications (3)

Publication Number Publication Date
JP2023502182A JP2023502182A (ja) 2023-01-20
JP2023502182A5 JP2023502182A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7859982B2 true JP7859982B2 (ja) 2026-05-15

Family

ID=73835687

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554171A Active JP7859982B2 (ja) 2019-11-12 2020-11-12 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法
JP2025052649A Pending JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025052649A Pending JP2025092573A (ja) 2019-11-12 2025-03-26 がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法

Country Status (8)

Country Link
US (2) US12286403B2 (cg-RX-API-DMAC7.html)
EP (1) EP4041402A1 (cg-RX-API-DMAC7.html)
JP (2) JP7859982B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220100904A (cg-RX-API-DMAC7.html)
CN (2) CN118286450A (cg-RX-API-DMAC7.html)
AU (2) AU2020384481B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159783A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021096542A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
WO2025121339A1 (ja) * 2023-12-04 2025-06-12 株式会社アンビシオン リポソーム剤、nkt細胞活性化剤、医薬組成物、およびこれらの用途
CN119792580A (zh) * 2025-01-02 2025-04-11 浙江大学 ID3 mRNA脂质纳米颗粒制备方法及在眼角膜疾病治疗中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521068A (ja) 2015-07-15 2018-08-02 セレーター ファーマシューティカルズ インコーポレイテッド 改善されたナノ粒子送達系
JP2019523757A (ja) 2016-05-20 2019-08-29 ザ ユニバーシティ オブ シカゴThe University Of Chicago 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
EP1773846A4 (en) 2004-07-13 2008-10-08 Univ British Columbia INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス, インコーポレイテッド Ido阻害剤
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
PT104158B (pt) 2008-08-18 2011-02-24 Univ Do Minho Aplicação da monooleína como novo lípido adjuvante em lipofecção
US8934953B2 (en) 2011-05-04 2015-01-13 Meridian Medical Systems, Llc Dual mode temperature transducer with oxygen saturation sensor
CN103857384B (zh) 2011-06-06 2017-07-11 大学健康网络 用于合成卟啉‑磷脂结合物的方法
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
BR112015022462A8 (pt) 2013-03-15 2019-11-26 Bristol Myers Squibb Co inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CN105777770B (zh) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
PE20180928A1 (es) 2015-07-24 2018-06-08 Newlink Genetics Corp Sales y profarmacos de 1-metil-d-triptofano
WO2017023667A1 (en) 2015-07-31 2017-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunostimulatory nanocarrier
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
CN108472245A (zh) 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
EP3400218A4 (en) 2016-01-08 2019-09-18 Euclises Pharmaceuticals, Inc. COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
US9624185B1 (en) 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
CN108424434B (zh) * 2017-02-13 2020-07-28 四川大学 氯喹胆固醇衍生物及其制备方法和用途
CA3063932A1 (en) * 2017-05-18 2018-11-12 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
WO2019057123A1 (zh) * 2017-09-20 2019-03-28 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN110025789A (zh) * 2019-04-01 2019-07-19 东南大学 一种药物磷脂化合物及其药物组合物和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521068A (ja) 2015-07-15 2018-08-02 セレーター ファーマシューティカルズ インコーポレイテッド 改善されたナノ粒子送達系
JP2019523757A (ja) 2016-05-20 2019-08-29 ザ ユニバーシティ オブ シカゴThe University Of Chicago 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Lu, J. et al.,Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression,Nature Communications,2017年,Vol.8, No.1,1811,doi:10.1038/s41467-017-01651-9
Pham, K. N., & Yeh, S. R.,Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1,Journal of the American Chemical Society,2018年,Vol.140, No.44,p.14538-14541,doi:10.1021/jacs.8b07994
Prendergast, G. C. et al.,Discovery of IDO1 Inhibitors: From Bench to Bedside,Cancer Research,2017年,Vol.77, No.24,p.6795-6811,doi:10.1158/0008-5472.CAN-17-2285

Also Published As

Publication number Publication date
AU2026201779A1 (en) 2026-03-26
US12286403B2 (en) 2025-04-29
CN118286450A (zh) 2024-07-05
CN115135385A (zh) 2022-09-30
JP2023502182A (ja) 2023-01-20
AU2020384481A1 (en) 2022-06-09
CN115135385B (zh) 2024-05-10
CA3159783A1 (en) 2021-05-20
US20250313531A1 (en) 2025-10-09
AU2020384481B2 (en) 2025-12-11
WO2021096542A1 (en) 2021-05-20
EP4041402A1 (en) 2022-08-17
US20210163418A1 (en) 2021-06-03
JP2025092573A (ja) 2025-06-19
KR20220100904A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
US12311010B2 (en) Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
US20250313531A1 (en) Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
US20250032620A1 (en) Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
AU2022393147A1 (en) Formulated and/or co-formulated nanocarriers compositions containing immunogenic cell death (icd) inducing prodrugs useful in the treatment of cancer and methods thereof
US12059470B2 (en) Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
JP2024510613A (ja) がんの処置に有用なA2aRアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物ならびにその方法
WO2025058654A1 (en) Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
EP2878312A1 (en) Reversible PEGylation of nanocarriers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260430

R150 Certificate of patent or registration of utility model

Ref document number: 7859982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150